Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 19/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588084 | 0.90 | GRM4 (0.68) | GRM4 | |
| SCHEMBL2591002 | 0.88 | GRM4 (0.64) | GRM4 | |
| SCHEMBL2591117 | 0.85 | GRM4 (0.66) | GRM4NPC1MAPTOPRK1HTT | |
| SCHEMBL2594309 | 0.84 | GRM4 (0.69) | GRM4 | |
| SCHEMBL2593618 | 0.84 | GRM4 (0.66) | GRM4NPC1MAPTOPRK1HTT | |
| SCHEMBL2592449 | 0.83 | GRM4 (0.67) | GRM4NPC1MAPTOPRK1HTT | |
| SCHEMBL2591744 | 0.82 | GRM4 (0.64) | GRM4 | |
| SCHEMBL15045105 | 0.79 | LMNA (0.69) | GRM4NPC1MAPTOPRK1HTT | |
| SCHEMBL12182111 | 0.78 | GRM4 (1.00) | GRM4 | |
| SCHEMBL2590992 | 0.77 | GRM4 (0.64) | GRM4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192603-B2 | Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130158078-A1 | Heterocyclic Sulfone MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2568809-A1 | HETEROCYCLIC SULFONE MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | Vanderbilt University (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011143466-A1 | HETEROCYCLIC SULFONE MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158078-A1 | Heterocyclic Sulfone MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRM4, GRIK4, GRIA4 | GRM4 1/4885NPC1 3626/4885MAPT 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.